FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific MOST POPULAR Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... March 23, 2021 ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... July 4, 2025 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... December 17, 2021 Load more HOT NEWS Breaking down changes in NHS cancer waiting times in England First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... Michelle Mitchell: Cancer is a fixable problem Scientists Find Genetic Changes Linked to Cancer in Children
